Announcements Trials
Browse Landscape

Phase

Phase 2 138Phase 1 57Phase 3 48Phase 1/2 36Phase 4 11Phase 2/3 5Phase NA 3Phase EARLY_PHASE1 3

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3OTHER_GOV 1FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × enzalutamide × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Zhongnan Hospital

Phase 2/3 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting
11,992 enrolled
Genitourinary

Prostatic Neoplasms

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed
100 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡